Literature DB >> 35606576

Clinical analysis of the etiological spectrum of bilateral adrenal lesions: A large retrospective, single-center study.

Fangfang Yan1,2, Jinyang Zeng1,2, Yulong Chen2, Yu Cheng2, Yu Pei2, Li Zang2, Kang Chen2, Weijun Gu2, Jin Du2, Qinghua Guo2, Xianling Wang2, Jianming Ba2, Zhaohui Lyu2, Jingtao Dou2, Guoqing Yang3, Yiming Mu4.   

Abstract

PURPOSE: To investigate the clinical characteristics, endocrinological function, and etiology of bilateral adrenal lesions in hospitalized patients.
METHODS: A retrospective study of 777 patients with bilateral adrenal lesions was conducted at the Chinese People's Liberation Army General Hospital between January 2013 and January 2018. Patients' demographic features, hormonal profiles, imaging findings, and histopathological findings were reviewed from database records.
RESULTS: Of the 777 patients with bilateral adrenal lesions, 495 were men. The mean age at diagnosis was 52.0 ± 13.0 years. Overall, 511 (65.8%) cases were benign, followed by adrenal metastases (n = 224, 28.8%), pheochromocytoma (n = 26, 3.3%), adrenal lymphoma (n = 9, 1.2%), and adrenal corticocarcinoma (ACC; n = 7, 0.9%). Hormonal evaluation revealed that 34.3% of bilateral adrenal lesions were functional. The primary etiologies of functional lesions were primary aldosteronism (16.6%, 129/777), and primary bilateral macronodular adrenocortical hyperplasia (PBMAH; 8.8%, 68/777). Patients with lymphoma and metastases were significantly older than those with benign nonfunctional lesions (60.4 ± 11.0 years vs. 54.5 ± 10.4 years and 57.9 ± 10.8 years vs. 54.5 ± 10.4 years, respectively; both P < 0.001). Lesions in patients with adrenal lymphoma, ACC, pheochromocytoma, metastases, congenital adrenal hyperplasia, tuberculosis, and Cushing's syndrome were significantly larger than benign nonfunctional lesions (all P < 0.001).
CONCLUSION: Benign adrenal lesions and metastases from the lungs are the most common causes of bilateral adrenal lesions. Primary aldosteronism and PBMAH are the most prevalent functional lesions. Moreover, patients with lymphoma or metastases are older and their masses are larger.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Benign; Bilateral adrenal lesions; Cushing syndrome; Malignant; Pheochromocytoma; Primary aldosteronism

Mesh:

Year:  2022        PMID: 35606576     DOI: 10.1007/s12020-022-03077-w

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.925


  22 in total

1.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; John Newell-Price; Martin O Savage; Paul M Stewart; Victor M Montori
Journal:  J Clin Endocrinol Metab       Date:  2008-03-11       Impact factor: 5.958

2.  Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature.

Authors:  G W Boland; M J Lee; G S Gazelle; E F Halpern; M M McNicholas; P R Mueller
Journal:  AJR Am J Roentgenol       Date:  1998-07       Impact factor: 3.959

3.  Diagnostic accuracy of computed tomography to identify adenomas among adrenal incidentalomas in an endocrinological population.

Authors:  M Marty; D Gaye; P Perez; C Auder; M L Nunes; A Ferriere; M Haissaguerre; A Tabarin
Journal:  Eur J Endocrinol       Date:  2018-02-21       Impact factor: 6.664

4.  The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment: An Endocrine Society Clinical Practice Guideline.

Authors:  John W Funder; Robert M Carey; Franco Mantero; M Hassan Murad; Martin Reincke; Hirotaka Shibata; Michael Stowasser; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2016-03-02       Impact factor: 5.958

5.  European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

Authors:  Martin Fassnacht; Olaf Dekkers; Tobias Else; Eric Baudin; Alfredo Berruti; Ronald de Krijger; Harm Haak; Radu Mihai; Guillaume Assie; Massimo Terzolo
Journal:  Eur J Endocrinol       Date:  2018-10-01       Impact factor: 6.664

Review 6.  Congenital Adrenal Hyperplasia-Current Insights in Pathophysiology, Diagnostics, and Management.

Authors:  Hedi L Claahsen-van der Grinten; Phyllis W Speiser; S Faisal Ahmed; Wiebke Arlt; Richard J Auchus; Henrik Falhammar; Christa E Flück; Leonardo Guasti; Angela Huebner; Barbara B M Kortmann; Nils Krone; Deborah P Merke; Walter L Miller; Anna Nordenström; Nicole Reisch; David E Sandberg; Nike M M L Stikkelbroeck; Philippe Touraine; Agustini Utari; Stefan A Wudy; Perrin C White
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 7.  ACTH-independent Cushing's syndrome with bilateral cortisol-secreting adrenal adenomas: a case report and review of literatures.

Authors:  Jia Wei; Sheyu Li; Qilin Liu; Yuchun Zhu; Nianwei Wu; Ying Tang; Qianrui Li; Kaiyun Ren; Qianying Zhang; Yerong Yu; Zhenmei An; Jing Chen; Jianwei Li
Journal:  BMC Endocr Disord       Date:  2018-04-23       Impact factor: 2.763

Review 8.  Overview of the 2022 WHO Classification of Adrenal Cortical Tumors.

Authors:  Ozgur Mete; Lori A Erickson; C Christofer Juhlin; Ronald R de Krijger; Hironobu Sasano; Marco Volante; Mauro G Papotti
Journal:  Endocr Pathol       Date:  2022-03-14       Impact factor: 4.056

9.  Bilateral adrenal masses: a single-centre experience.

Authors:  Nilesh Lomte; Tushar Bandgar; Shruti Khare; Swati Jadhav; Anurag Lila; Manjunath Goroshi; Rajeev Kasaliwal; Kranti Khadilkar; Nalini S Shah
Journal:  Endocr Connect       Date:  2016-04-01       Impact factor: 3.335

10.  Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas.

Authors:  R Garcia-Carbonero; F Matute Teresa; E Mercader-Cidoncha; M Mitjavila-Casanovas; M Robledo; I Tena; C Alvarez-Escola; M Arístegui; M R Bella-Cueto; C Ferrer-Albiach; F A Hanzu
Journal:  Clin Transl Oncol       Date:  2021-05-06       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.